

1 **Comparative adverse effects, perceptions and attitudes related to BNT162b2,**
2 **mRNA1273, or JNJ-78436735 SARS-CoV-2 vaccines: A population-based**
3 **longitudinal cohort**

4
5 **Authors**

6 Oliver Bürzle¹, Dominik Menges¹, Julian D. Maier¹, Daniel Schams¹, Milo Puhan¹, Jan Fehr¹, Tala
7 Ballouz^{1*}, Anja Frei^{1*}

8
9 * Shared last authorship due to equal contribution.

10 ¹ Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich,
11 Switzerland

12
13 **Corresponding Author**

14 Anja Frei, PhD

15 Epidemiology, Biostatistics and Prevention Institute, University of Zurich

16 Hirschengraben 84, 8001 Zurich, Switzerland

17 E-Mail: anja.frei@uzh.ch | Phone: +41 44 634 43 60

18

19 **Alternate Corresponding Author**

20 Jan Fehr, MD

21 Epidemiology, Biostatistics and Prevention Institute, University of Zurich

22 Hirschengraben 84, 8001 Zurich, Switzerland

23 E-Mail: jan.fehr@uzh.ch | Phone: +41 44 634 46 79

24

25 **Keywords:** SARS-CoV-2, vaccination, adverse effects, hesitancy, real-world data

26

27 **Running title:** SARS-CoV-2 vaccination adverse effects

28

29 **Main Points:** Our representative population-based cohort study demonstrated the safety of
30 three SARS-CoV-2 vaccines and provides real-world estimates on adverse effect incidence.

31 Transparent communication of expected adverse effects to vaccine-seeking individuals is pivotal
32 to build trust in current or future vaccination campaigns.

33

34 **Abstract**

35 **Importance:** Long-term control of SARS-CoV-2 requires effective vaccination strategies. This has
36 been challenged by public mistrust and spread of misinformation regarding vaccine safety.
37 Hence, better understanding and communication on the longer-term and comparative
38 experiences of general population individuals following SARS-CoV-2 vaccination are required.

39

40 **Objective:** To evaluate and compare self-reported adverse effects following SARS-CoV-2
41 vaccination, participants' perceptions regarding vaccinations and their compliance with
42 recommended public health measures.

43

44 **Design, Setting and Participants:** Population-based longitudinal cohort of 575 adults, randomly
45 selected from all individuals presenting to the reference vaccination center of the Canton of
46 Zurich, Switzerland, for receipt of BNT162b2, mRNA1273, or JNJ-78436735.

47

48 **Exposures:** BNT162b2, mRNA1273, or JNJ-78436735 vaccines.

49

50 **Main Outcomes and Measures:** Primary outcomes included period prevalence, onset, duration,
51 and severity of self-reported adverse effects over 12 weeks following vaccination with a specific
52 focus on the proportion of participants reporting allergic reactions, menstrual irregularities, or
53 cardiac adverse effects, or requiring hospitalization. Secondary outcomes included risk factors
54 associated with reporting adverse effects, perception of vaccine importance, trust in public

55 health authorities and pharmaceutical companies, and compliance with recommended public
56 health measures.

57

58 **Results:** 454 (79.0%) participants reported at least one adverse effect during 12 weeks after
59 vaccination. Prevalence was highest among mRNA-1273 recipients (88.7% vs. 77.3% after
60 BNT162b2, 69.1% after JNJ-78436735). Most adverse effects were systemic (72%), occurred
61 within 24 hours (67.9%), and resolved in less than three days (76.3%). 85.2% were reported as
62 mild or moderate. Allergic reactions were reported by 0.4% of participants, hospitalizations by
63 0.7%, cardiac adverse effects by 1.4%. Menstrual irregularities were reported by 9% of female
64 participants younger than 50 years. Female sex, younger age, higher education, and receipt of
65 mRNA-1273 were associated with reporting adverse effects. Compared to JNJ-78436735
66 recipients, a higher proportion of mRNA vaccine recipients agreed that vaccination is important
67 (87.5% vs. 28.5%), and trusted public health authorities (80.2% vs. 30.3%) and pharmaceutical
68 companies (71.7% vs. 23.6%).

69

70 **Conclusions and Relevance:** Our population-based cohort provided real-world data on self-
71 reported adverse effects following SARS-CoV-2 vaccination and highlights the importance of
72 transparent communication regarding adverse effects and building trust in public health
73 authorities to ensure successful future vaccination campaigns.

74

75 **Introduction**

76 Beginning with the first vaccinations against SARS-CoV-2 in December 2020, the largest global
77 vaccination campaign in recent history captured the public and professional attention for
78 months. Apart from the obvious focus on efficacy, concerns about vaccine-related adverse
79 effects dominated the professional and public discourse during the campaign. The fast-track
80 authorization of the technologically new mRNA vaccines BNT162b2 (Pfizer-BioNTech) and
81 mRNA1273 (Moderna) in some countries and misinformation contributed to vaccine skepticism
82 and hesitancy.[1-5] This highlights the importance of understanding and accurately
83 communicating information regarding adverse effects, including vaccine safety profiles, to
84 improve vaccine confidence and uptake.

85 The current body of evidence on adverse effects following SARS-CoV-2 vaccination consists
86 mostly of data reported in randomized clinical trials (RCTs) and reports to government-based
87 surveillance systems, such as the European EudraVigilance, US VAERS (Vaccine Adverse Event
88 Reporting System), or Swiss ELViS (Electronic Vigilance System). Adverse effects reported in RCTs
89 have been primarily mild and self-limited,[6, 7] with systemic reactions (e.g. fatigue, headache,
90 pain) and local injection site reactions (e.g. pain, erythema, swelling) being the most frequent.[8-
91 10] In contrast, severe adverse effects accounted for a significantly higher proportion of reports
92 in governmental surveillance systems.[11-13] This was to be expected as reporting to surveillance
93 systems is subject to several biases including underreporting of mild and common adverse effects
94 and increased reporting of those which are severe or widely reported in the media.[14, 15]
95 Although RCTs provided important evidence on the safety of individual vaccines, they offered
96 little side-by-side comparisons. Furthermore, RCTs yield data collected on selected populations

97 raising the issue of how well this data correlates to “real-world” experiences. The few studies
98 eliciting patient-reported symptoms following different vaccines in real-world settings often had
99 cross-sectional designs and were conducted among very specific groups such as healthcare
100 workers or university students, which may not be representative of the general population.[6, 7]
101 In this population-based study, we aimed to deliver a comprehensive comparative analysis of
102 self-reported adverse effects up to 12 weeks after receipt of three SARS-CoV-2 vaccines approved
103 in Switzerland in 2021. Further objectives were to examine the general perception and attitudes
104 of individuals regarding SARS-CoV-2 vaccination and their compliance with recommended public
105 health measures. Thereby, we aim to improve our understanding of the adverse health effects
106 experienced following vaccination in the general population to provide an evidence base for
107 future vaccination campaigns in view of the likely implementation of additional booster
108 vaccinations and updated SARS-CoV-2 vaccines.

109


110 **Methods**

111 **Study design, participants, and recruitment**

112 This study is based on the Zurich SARS-CoV-2 Vaccine Cohort, an ongoing prospective population-
113 based cohort study. We recruited participants between March 10, 2021, and January 27, 2022,
114 at the University of Zurich’s (UZH) vaccination center, the reference center for the Canton of
115 Zurich, Switzerland. All individuals scheduled to receive one of the SARS-CoV-2 vaccines approved
116 in Switzerland in 2021, BNT162b2 (Pfizer-BioNTech), mRNA1273 (Moderna), or JNJ-78436735
117 (Johnson & Johnson), were screened for eligibility. Eligibility criteria were being 18 years or older,

118 being able to follow study procedures, having sufficient knowledge of the German language and
119 residing in the Canton of Zurich. We excluded individuals who had already received a first dose
120 of a SARS-CoV-2 vaccine. A daily age-stratified (18-64 years, 65 years or older) random sample
121 was selected separately for each approved vaccine from all eligible individuals belonging to the
122 following vaccination groups as defined by the Canton of Zurich [16, 17]: “Over 75 years”, “over
123 65 years”, “between 50–64 years”, and “between 18–49 years”. We excluded individuals
124 belonging to groups specific for “healthcare workers”, “caretakers of high-risk patients”,
125 “individuals living in communal facilities”, and “individuals with the highest risk diseases” to
126 ensure that that our sample was representative of the general population.[18, 19] Randomly
127 selected individuals were then invited to participate in our study. We obtained written informed
128 consent from all participants. We were unable to reach the desired sample size for JNJ-78436735
129 recipients 65 years or older, due to limited demand.

130 The study protocol was prospectively registered on the International Standard Randomized
131 Controlled Trial Number Registry (ISRCTN 15499304) and approved by the ethics committee of
132 the Canton of Zurich (BASEC 2021-00273).



133

134 **Figure 1.** Recruitment of study cohort

135

136 **Data sources and measurements**

137 Upon enrolment, all participants completed a baseline questionnaire including questions on their
 138 sociodemographics, medical and smoking history, SARS-CoV-2 related information such as prior
 139 infections, perceptions and attitudes regarding vaccination, trust in public health authorities and
 140 pharmaceutical companies, and compliance with recommended public health measures
 141 (including use of the SwissCovid digital proximity tracing app). Perception, attitude, and

142 compliance questions were collected using a numerical scale (0 “Very low opinion”, to 100 “Very
143 high opinion” for perception), or a 5-item Likert (ranging from “Strongly disagree” to “Strongly
144 agree” for trust-related statements, and from “Never/Impossible” to “Always” for statements on
145 compliance with public health measures). We pooled BNT162b2 and mRNA-1273 recipients into
146 one “mRNA vaccine” group since they expressed similar perceptions towards vaccination and
147 compliance with recommended measures (Supplement 1).

148 We provided participants with a paper symptom diary and instructed them to record any adverse
149 effect they experienced during 12 weeks after vaccination, as free text, including start and end
150 dates, perceived severity (on a 5-item Likert scale, ranging from “Very mild” to “Very severe”),
151 and consequences of the adverse effects (i.e., self-medication, need for healthcare services, or
152 hospitalizations). Symptom diaries were collected at the 12-week follow-up visit. Participants
153 received additional electronic questionnaires at 4, 6, and 12 weeks, in which they were asked to
154 report any positive SARS-CoV-2 polymerase chain reaction (PCR) or rapid antigen tests. We
155 excluded all reported adverse effects starting within three days before and at any timepoint after
156 positive SARS-CoV-2 tests to ensure that reported symptoms were related to vaccination rather
157 than infection. To determine the proportion of participants with past SARS-CoV-2 infection, we
158 measured participants’ anti-SARS-CoV-2 Spike (S)-IgA and IgG antibodies at baseline using a
159 highly sensitive and specific Luminex technology-based assay.[20]

160 We collected and managed all study data using the Research Electronic Data Capture (REDCap)
161 system.[21, 22]

162

163 **Outcomes**

164 Our primary outcomes included period prevalence, onset, duration, and severity of self-reported
165 adverse effects over 12 weeks following vaccination, with a specific focus on the proportion of
166 participants reporting allergic reactions, menstrual irregularities, or cardiac adverse effects, or
167 requiring hospitalization. Secondary outcomes included risk factors associated with adverse
168 effect reports, general perceptions and attitudes regarding vaccination, trust in public health
169 authorities and pharmaceutical companies, and compliance with recommended public health
170 measures.

171

172 **Statistical Analysis**

173 We descriptively analyzed the characteristics and outcomes of interest for the overall cohort and
174 for each of the three vaccine groups. Continuous variables are reported as median with
175 interquartile range (IQR); categorical or ordinal variables as frequencies (N) and percentages
176 (%). We coded adverse effect data reported by participants in the symptom diary according to
177 the Medical Dictionary for Regulatory Activities (MedDRA) hierarchical terminology (Supplement
178 2).[23] The self-reported adverse effects were translated from German to the closest matching
179 MedDRA “low level term”. All corresponding higher-level terms were included in the database, a
180 highest level of coding was added, labelling each adverse effect either as “local” or “systemic”.
181 We explored associations of several predictor variables on the outcome of reporting one or more
182 adverse effects using a multivariable logistic regression model. Age, sex, vaccine type and
183 education were included a priori variables in the model based on findings from other studies.[6]

184 Results are presented as odds ratios (OR) with their 95% confidence intervals (CI) and two-sided
185 p-value. All analyses were performed using R (version 4.1.2).

186

187 **Results**

188 **Cohort characteristics**

189 Of our 575 participants, 323 participants (56.2%) were female, and the median age was 59 years
190 (IQR 41 to 70) (Table 1). 411 (71.5%) participants received a mRNA-based vaccine (2 doses 3 to 4
191 weeks apart, 36.2% BNT162b2 and 35.3% mRNA-1273) and 164 (28.5%) received a vector-based
192 vaccine (1 dose, JNJ-78436735). The proportion of participants with a higher level of education
193 (39.8% vs 61.8%) was lower among JNJ-78436735 recipients compared to mRNA vaccine
194 recipients.

195 37 participants (6.4%) reported ever having a positive SARS-CoV-2 test prior to vaccination, with
196 a higher proportion among JNJ-78436735 recipients (9.7% vs 6.4% of mRNA-1273 and 3.7% of
197 BNT162b2 recipients). 19 (9.2%) BNT162b2 recipients, 24 (11.8%) mRNA-1273 recipients and 29
198 (17.6%) JNJ-78436735 recipients tested seropositive for anti-SARS-CoV-2 S-IgA or -IgG before
199 receiving the first vaccination dose.

200

201 **Table 1.** Demographic and clinical characteristics of study population

	BNT162b2 (Pfizer/BioNTech)	mRNA-1273 (Moderna)	JNJ-78436735 (Johnson & Johnson)	Overall
	(N=207)	(N=203)	(N=165)	(N=575)
Age, median (IQR) -in years	59 (36 to 75)	65 (42.5 to 69)	58 (45 to 70)	59 (41 to 70)
Age distribution - no. of participants (%)				
<65 years	106 (51.2%)	99 (48.8%)	103 (62.4%)	308 (53.6%)
≥65 years	101 (48.8%)	104 (51.2%)	62 (37.6%)	267 (46.4%)
Female sex - no. of participants (%)	115 (55.6%)	120 (59.1%)	88 (53.3%)	323 (56.2%)
Presence of at least one preexisting medical condition (%)	80 (40.8%)	78 (42.2%)	64 (43.2%)	222 (42.0%)
Highest educational level - no. of participants (%)				
None or mandatory school	9 (4.4%)	4 (2.0%)	7 (4.3%)	20 (3.5%)
Vocational training or specialized baccalaureate	71 (34.5%)	72 (35.6%)	91 (55.8%)	234 (41.0%)
Higher technical school or college	46 (22.3%)	44 (21.8%)	40 (24.5%)	130 (22.8%)
University	80 (38.8%)	82 (40.6%)	25 (15.3%)	187 (32.7%)
Missing	1 (0.5%)	1 (0.5%)	2 (1.2%)	4 (0.7%)
Reported adverse effects - no. of participants (%)	160 (77.3%)	180 (88.7%)	114 (69.1%)	456 (79.3%)
Tested seropositive for anti-SARS-CoV-2 S-IgA at baseline - no. of participants (%)	12 (5.8%)	14 (6.9%)	20 (12.1%)	46 (8.0%)
Tested seropositive for anti-SARS-CoV-2 S-IgG at baseline - no. of participants (%)	15 (7.2%)	19 (9.4%)	24 (14.5%)	58 (10.1%)

Reported positive SARS-CoV-2 test prior to baseline - no. of participants (%)	8 (3.9%)	13 (6.4%)	16 (9.7%)	37 (6.4%)
SARS-CoV-2 Infection prior to baseline (self-reported infection or tested seropositive)- no. of participants (%)	21 (10.1%)	28 (13.8%)	31 (18.8%)	80 (13.9%)
Tested positive for anti-SARS-CoV-2 S-IgA or IgG at baseline with no report of prior SARS-CoV-2 Infection- no. of participants (%)	13 (6.3%)	15 (7.4%)	15 (9.1%)	43 (7.5%)

202


203 **Frequency and characteristics of adverse effects**

204 Overall, 79.0% (N= 454) of all participants reported at least one adverse effect up to three months
205 following vaccination, with a total of 2397 reported adverse effects. The highest proportion of
206 participants with adverse effects after vaccination was among mRNA-1273 recipients (88.7%,
207 N=180) compared to BNT162b2 (77.3%, N=160) and JNJ-78436735 (69.1%, N=114) recipients.
208 Based on a multivariable logistic regression model, we found strong to very strong evidence that
209 female sex (OR=4.05 (95% CI: 2.33 to 7.3), p<0.001), higher education levels (vs. none or
210 mandatory school, OR=6.26 (1.86 to 21.2), p=0.003) and receiving mRNA-1273 (vs. BNT162b2,
211 OR=2.38 (1.22 to 4.8), p=0.013) were associated with adverse effect reports. There was weak
212 evidence that younger age (<65 vs. ≥65 years, OR=1.65 (0.96 to 2.9), p=0.072) was associated
213 with adverse effects. We found no evidence that JNJ-78436735 (vs. BNT162b2), preexisting
214 conditions, low opinion (opinion value <50) about vaccination and SARS-CoV-2 infections prior to
215 vaccination were associated with adverse effects (Supplement 3).

216 More participants reported systemic (71.7%, N=412) than local adverse effects (54.8%, N=315).
217 Among mRNA vaccine recipients, the proportion of systemic among all adverse effects increased
218 after the 2nd dose (63.9% to 77.2% in BNT162b2 and 59.1% to 78.0% in mRNA-1273 recipients,
219 Supplement 4). The most common adverse effect mentioned by mRNA vaccine recipients was
220 local pain (54.1% of BNT162b2 and 69.5% of mRNA-1273 recipients), followed by asthenia
221 (fatigue; 38.7% of BNT162b2 and 44.8% of mRNA-1273 recipients). JNJ-78436735 recipients most
222 frequently reported headache (36.4%), followed by local pain (30.9%) and asthenia (30.9%).
223 Other commonly reported adverse effects included nausea, vertigo, and sore throat (all >5%). Of
224 our participants, 0.4% (n=2) (one BNT162b2 and one mRNA-1273 recipient) reported allergic
225 reactions. Adverse effects affecting menstruation were reported by 5 out of 47 (10.6%) female
226 participants younger than 50 among BNT162b2 recipients, 4 out of 42 (9.5%) among mRNA-1273
227 recipients and 2 out of 31 (6.5%) among JNJ-78436735 recipients (six participants reported cycle
228 irregularities, three heavy menstrual bleeding, three intermenstrual bleeding). Tachycardia or
229 palpitations were reported by seven (1.2%) participants, four mRNA-1273, two JNJ-78436735 and
230 one BNT162b2 recipient. One BNT162b2 recipient reported pericardial effusion and atrial
231 fibrillation after the second dose.
232 Most adverse effects (83.9%) occurred in the first week following vaccination, 67.9% within 24
233 hours. Participants reported that adverse effects lasted for 3.9 days on average, and most
234 resolved within 3 (76.3%) days. Asthenia, extremity pain, and cough were most frequently
235 reported to last longer than a week. Adverse effect onset and duration were similar across the
236 three vaccines (Figure 2A, Supplement 5).


237 The perceived severity of most adverse effects was mild (49.0%) or moderate (36.2%).
238 Meanwhile, 14.7% were described as severe (13.4%) or very severe (1.3%), with the highest
239 proportion of severe to very severe adverse effects reported after JNJ-78436735 (18.3% vs 16.1%
240 after mRNA-1273, 9.4% after BNT162b2). Asthenia (13.1%), headache (12.8%) and pain (9.4%)
241 were mostly reported as severe or very severe adverse effects. Hospitalization due to reported
242 adverse effects was reported by 0.7% (n=4) of participants (two BNT162b2 recipients with loss of
243 consciousness and bullous pemphigoid, one mRNA-1273 recipient with retinal detachment and
244 one JNJ-78436735 recipient with meningitis).

245 Most reported adverse effects resolved spontaneously (Figure 2C). However, participants
246 reported using self-prescribed medications (e.g., Paracetamol or Ibuprofen) or seeking
247 consultation with a healthcare provider for 448 (18.7%) and 84 (3.5%) of the adverse effects,
248 respectively.



249

250 **Figure 2.** Frequency of any, local and systemic adverse effects. Panel A shows five most common systemic and local
 251 adverse effects in overall sample (N=575). Panel B shows adverse effects by vaccine type (BNT162b2 N=208, mRNA-
 252 1273 N=203, JNJ-78436735 N=164).




253
254 **Figure 3.** Characteristics of self-reported adverse effects. Panel A shows the time of adverse effect onset by vaccine,
255 panel B perceived adverse effect severity by vaccine and panel C the consequences of adverse effects by vaccine.
256 (ER: Emergency Room)

257
258 **Perceptions of vaccination and compliance with recommended public health measures**

259 More mRNA vaccine recipients (87.5%) agreed completely or in part with the statement that it
260 was important to be vaccinated compared to 28.5% of JNJ-78436735 recipients. Similarly, more
261 mRNA vaccine recipients felt that vaccines were a part of a healthy lifestyle (63.6% vs. 28.9% of
262 JNJ-78436735 recipients). Trust in public health authorities (80.2% vs. 30.3%) and pharmaceutical
263 companies (71.7% vs. 23.6%) was higher among mRNA vaccine recipients compared to JNJ-

264 78436735 recipients. Both groups felt they had sufficient understanding of how the vaccine
 265 helped the body fend off infectious diseases (89.3% mRNA vaccine recipients vs. 62.4% JNJ-
 266 78436735 recipients) and reported similar compliance with recommended public health
 267 measures (Figure 3B). Use of the SwissCovid digital proximity tracing app was higher among
 268 mRNA vaccine recipients compared to JNJ-78436735 recipients (53.2% vs 27.4%).



269
 270 **Figure 4.** Perception of vaccination and compliance with recommended public health measures.
 271

272 **Discussion**

273 In this population-based cohort of 575 individuals who received a SARS-CoV-2 vaccine and were
274 followed-up over 12 weeks, participants commonly reported adverse effects, namely local pain,
275 fatigue, headache, and fever. Most adverse effects were mild to moderate and resolved within
276 three days. Allergic reactions (0.4%) and adverse effects requiring hospitalization (0.7%) were
277 rare. Around 9% of female participants younger than 50 reported menstrual cycle changes, more
278 frequently among mRNA vaccine recipients. Female sex, receiving mRNA-1273, higher education
279 and younger age were associated with experiencing adverse effects. JNJ-78436735 recipients less
280 frequently perceived vaccination to be important and had lower trust in public health authorities
281 and pharmaceutical companies compared to mRNA vaccine recipients. There were no differences
282 between vaccine groups in compliance with preventive public health measures.

283 Our results on the prevalence and severity of adverse effects are in line with previously
284 reported data from RCTs and other observational studies.[6, 9, 10, 24-26] In an online survey
285 among individuals vaccinated with either BNT162b2, mRNA-1273, or JNJ-78436735, Beatty et
286 al. reported that 80.3% of participants experienced adverse effects, with comparable estimates
287 for each vaccine type.[6] Our data also matches the prevalence published in the RCTs for each
288 vaccine individually.[8-10]. The proportion of adverse effects that were self-assessed to be
289 severe or required hospitalization in our study (14.8%) was well below that of Swiss and
290 European governmental surveillance systems (37.9% in Swiss ELViS).[11, 12] US surveillance
291 reports also stated higher estimates of serious adverse events based on hospitalization rates,
292 serious illness and deaths (9.2% vs. our 0.7%).[13] These higher estimates from governmental
293 reporting systems are likely related to the underreporting of mild symptoms and underscore

294 the importance of “real-world” data.[14, 15] There is wide variation in reports on prevalence of
295 anaphylaxis and severe allergic reactions ranging from 0.03% to 3%, due to differing
296 definitions.[6, 27, 28] In our study, two (0.4%) participants reported allergic reactions, without
297 requiring medical attention.

298 Our follow-up over 12 weeks allowed us to assess adverse effects that occur with some delay,
299 such as menstrual changes reported in 9% of female participants younger than 50 years. Few
300 studies have described menstrual irregularities following SARS-CoV-2 vaccination with
301 prevalence ranging between 0.3% and 46%.[29, 30] This large variability and the high prevalence
302 (37.8%) of menstrual irregularities in the general population regardless of vaccination underscore
303 the challenge of attributing changes in the menstrual cycle to vaccination.[31] Further research
304 is needed on the influence of SARS-CoV-2 vaccination on menstruation and the general impact
305 of vaccination on female recipients, as we and others observed that female recipients were
306 generally more likely to experience adverse effects.[32-35]

307 We also found that participants who were younger than 65 years and received mRNA-1273 were
308 more likely to report adverse effects possibly due to stronger immune responses among these
309 groups.[6, 13, 26] Similarly, other studies have found evidence that SARS-CoV-2 infections prior
310 to vaccination may be associated with adverse effects reports due to increased
311 immunogenicity.[6, 7] While we found that individuals with prior SARS-CoV-2 infections were 1.8
312 times more likely to report adverse effects compared to those without, the findings were not
313 statistically significant, potentially due to insufficient power in our study.

314 mRNA vaccine recipients trusted vaccines in general and thus were mostly motivated to be
315 vaccinated as soon as SARS-CoV-2 vaccines became available. JNJ-78436735 recipients were

316 more hesitant and waited for JNJ-78436735's introduction to Switzerland, resulting in a higher
317 proportion of individuals with infections prior to vaccination compared to mRNA vaccine
318 recipients. Other studies describe these concerns about the rapid development and fears of
319 adverse effects to be among the main reasons to wait for non-mRNA-based vaccines or other
320 alternatives.[36-38] General skepticism and the presence of nocebo effects , as demonstrated by
321 a Amanzio et al, may have translated into a higher proportion of JNJ-78436735 recipients
322 perceiving adverse effects as severe. [38-40] Increasing awareness of these nocebo responses
323 and using positive framing around the low risk of severe adverse effects may contribute to
324 improving vaccine acceptance.

325 This study provided evidence from a representative cohort recruited from the general population
326 and followed-up over a 12-week period. Data collected through symptom diaries and adverse
327 effect coding according to MedDRA terms generated a comprehensive dataset allowing a
328 comparative analysis of three common SARS-CoV-2 vaccines.

329 However, there are several limitations to our study. First, self-selection bias may have occurred
330 if individuals who are more health literate or less hesitant participated in our study, leading to
331 overestimations of trust in public health authorities and more positive perceptions of vaccines.
332 However, we consider the data on the prevalence of adverse effects as broadly representative.
333 Second, our data is self-reported. While this allows for an accurate description of vaccine
334 recipients' experiences, it is subjective and no verification of the relation of adverse effects and
335 vaccination by a healthcare provider was possible. Third, the absolute numbers of reports for
336 some adverse effects when analyzed individually are relatively small (e.g., menstrual changes).
337 Finally, our analysis was restricted to basic immunization of the three SARS-CoV-2 vaccines

338 approved in Switzerland at the time of study conduct. Further research on adverse effects
339 occurring after booster vaccinations, other types of vaccines and combinations of different
340 vaccines is needed.

341

342 **Conclusion**

343 This study demonstrates the safety of three SARS-CoV-2 vaccines in a representative population-
344 based cohort and provides real-world estimates on adverse effect prevalence after vaccination.
345 Thereby, we importantly extend the evidence base for health-care providers to answer many of
346 the questions of individuals seeking vaccination. While further evidence on adverse effects after
347 booster vaccination and other vaccine types is required, our study suggests that transparent
348 communication regarding adverse effects and building trust in public health authorities are
349 pivotal future vaccination campaigns' success.

350

351 **Funding**

352 This work was supported by funds received within the Corona Immunitas research network, of
353 which this study is part of. The Corona Immunitas research network is coordinated by the Swiss
354 School of Public Health (SSPH+) and funded by fundraising of SSPH+ including funds of the Swiss
355 Federal Office of Public Health and private funders (ethical guidelines for funding stated by
356 SSPH+ were respected), by funds of the cantons of Switzerland (Vaud, Zurich, and Basel), and by
357 institutional funds of the Universities. Additional funding specific for this cohort was received
358 from the Uniscientia Foundation (Switzerland). TB received funding from the European Union's
359 Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant
360 agreement No 801076, through the SSPH+ Global PhD Fellowship Programme in Public Health
361 Sciences (GlobalP3HS) of the SSPH+. DM received funding by the UZH Postdoc Grant, grant no.
362 FK-22-053.

363

364 **Acknowledgements**

365 The authors thank the study administration team and the team from the University of Zurich's
366 (UZH) vaccination center, the reference center for the Canton of Zurich, Switzerland, for their
367 dedicated support of the study. They also thank the study participants for their valuable
368 contribution to this project.

369

370 **Conflict of Interest**

371 The authors of this manuscript state no conflict of interest.

372 **References:**

- 373 1. O'Callaghan KP, Blatz AM, Offit PA. Developing a SARS-CoV-2 Vaccine at Warp Speed.
374 JAMA **2020**; 324(5): 437-8.
- 375 2. US Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine emergency use
376 authorization. Available at: <https://www.fda.gov/media/144412/download>. Accessed
377 June 22.
- 378 3. US Food and Drug Administration. Moderna COVID-19 vaccine emergency use
379 authorization. Available at: <https://www.fda.gov/media/144636/download>. Accessed
380 June 22.
- 381 4. Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ. COVID-19
382 Vaccination Hesitancy in the United States: A Rapid National Assessment. J Community
383 Health **2021**; 46(2): 270-7.
- 384 5. Cascini F, Pantovic A, Al-Ajlouni Y, Failla G, Ricciardi W. Attitudes, acceptance and
385 hesitancy among the general population worldwide to receive the COVID-19 vaccines and
386 their contributing factors: A systematic review. EClinicalMedicine **2021**; 40: 101113.
- 387 6. Beatty AL, Peyser ND, Butcher XE, et al. Analysis of COVID-19 Vaccine Type and Adverse
388 Effects Following Vaccination. JAMA Netw Open **2021**; 4(12): e2140364.
- 389 7. Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-Reported Real-World Safety and
390 Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. Life (Basel) **2021**; 11(3).
- 391 8. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S
392 Vaccine against Covid-19. N Engl J Med **2021**; 384(23): 2187-201.

- 393 9. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-
394 19 Vaccine. *N Engl J Med* **2020**; 383(27): 2603-15.
- 395 10. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
396 Vaccine. *N Engl J Med* **2021**; 384(5): 403-16.
- 397 11. Swissmedic. Reports of suspected adverse reactions to COVID-19 vaccines in Switzerland
398 – update 26. Available at:
399 [https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/covid-](https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/covid-19-vaccines-safety-update-16.html)
400 [19-vaccines-safety-update-16.html](https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/covid-19-vaccines-safety-update-16.html). Accessed 19 August.
- 401 12. European Medicines Agency. Safety of COVID-19 Vaccines. Available at:
402 [https://www.ema.europa.eu/en/human-regulatory/overview/public-health-](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/safety-covid-19-vaccines)
403 [threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/safety-](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/safety-covid-19-vaccines)
404 [covid-19-vaccines](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/safety-covid-19-vaccines). Accessed August 24.
- 405 13. Gee J, Marquez P, Su J, et al. First Month of COVID-19 Vaccine Safety Monitoring - United
406 States, December 14, 2020-January 13, 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(8):
407 283-8.
- 408 14. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine
409 Adverse Event Reporting System (VAERS). *Vaccine* **2015**; 33(36): 4398-405.
- 410 15. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for
411 vaccine adverse events. *Am J Public Health* **1995**; 85(12): 1706-9.
- 412 16. Canton Zurich. Coronavirus vaccination. Available at:
413 <https://www.zh.ch/en/gesundheit/coronavirus/coronavirus-impfung.html>. Accessed
414 13th July.

- 415 17. TravelClinic.ch. Impfgruppen. Available at: [travelclinic.ch/wp-](https://travelclinic.ch/wp-content/uploads/Impfgruppen.pdf)
416 [content/uploads/Impfgruppen.pdf](https://travelclinic.ch/wp-content/uploads/Impfgruppen.pdf). Accessed 13th July.
- 417 18. Federal Office of Public Health. Kategorien besonders gefährdeter Personen.
418 [bag.admin.ch](https://www.bag.admin.ch/bag/admin/ch): Federal Office of Public Health,, **2022** 10.08.2022.
- 419 19. Federal Office of Public Health. Covid-19-Impfstrategie (Stand 05.07.2022). [bag.admin.ch](https://www.bag.admin.ch/bag/admin/ch):
420 Federal Office of Public Health,, **2022** 05.07.2022.
- 421 20. Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein
422 Antibody Responses Impact the Estimates of Infections in Population-Based
423 Seroprevalence Studies. *J Virol* **2021**; 95(3).
- 424 21. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
425 community of software platform partners. *J Biomed Inform* **2019**; 95: 103208.
- 426 22. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
427 capture (REDCap)--a metadata-driven methodology and workflow process for providing
428 translational research informatics support. *J Biomed Inform* **2009**; 42(2): 377-81.
- 429 23. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA).
430 *Drug Saf* **1999**; 20(2): 109-17.
- 431 24. Thomas SJ, Moreira ED, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-
432 19 Vaccine through 6 Months. *N Engl J Med* **2021**; 385(19): 1761-73.
- 433 25. Jęskowiak I, Wiatrak B, Grosman-Dziewiszek P, Szelağ A. The Incidence and Severity of
434 Post-Vaccination Reactions after Vaccination against COVID-19. *Vaccines (Basel)* **2021**;
435 9(5).

- 436 26. Vigezzi GP, Lume A, Minerva M, et al. Safety surveillance after BNT162b2 mRNA COVID-
437 19 vaccination: results from a cross-sectional survey among staff of a large Italian teaching
438 hospital. *Acta Biomed* **2021**; 92(S6): e2021450.
- 439 27. Shimabukuro T. Allergic reactions including anaphylaxis after receipt of the first dose of
440 Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020. *Am J*
441 *Transplant* **2021**; 21(3): 1332-7.
- 442 28. Blumenthal KG, Robinson LB, Camargo CA, et al. Acute Allergic Reactions to mRNA COVID-
443 19 Vaccines. *JAMA* **2021**; 325(15): 1562-5.
- 444 29. Rogers A, Rooke E, Morant S, et al. Adverse events and overall health and well-being after
445 COVID-19 vaccination: interim results from the VAC4COVID cohort safety study. *BMJ*
446 *Open* **2022**; 12(6): e060583.
- 447 30. Lee KM, Junkins EJ, Fatima UA, Cox ML, Clancy KB. Characterizing menstrual bleeding
448 changes occurring after SARS-CoV-2 vaccination. *medRxiv* **2021**: 2021.10.11.21264863.
- 449 31. Trogstad L. Increased occurrence of menstrual disturbances in 18-to 30-year-old women
450 after COVID-19 vaccination. Available at SSRN 3998180 **2022**.
- 451 32. Ruggieri A, Anticoli S, D'Ambrosio A, Giordani L, Viora M. The influence of sex and gender
452 on immunity, infection and vaccination. *Ann Ist Super Sanita* **2016**; 52(2): 198-204.
- 453 33. Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to
454 vaccination. *Trans R Soc Trop Med Hyg* **2015**; 109(1): 9-15.
- 455 34. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and Gender Differences in the Outcomes
456 of Vaccination over the Life Course. *Annu Rev Cell Dev Biol* **2017**; 33: 577-99.

- 457 35. Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-
458 induced humoral immunity. *Semin Immunopathol* **2019**; 41(2): 239-49.
- 459 36. Wadman M. Novavax's long-awaited COVID-19 vaccine authorizations offer an alternative
460 to mRNA. Available at: [https://www.science.org/content/article/novavax-s-long-](https://www.science.org/content/article/novavax-s-long-awaited-covid-19-vaccine-authorizations-offer-alternative-mrna)
461 [awaited-covid-19-vaccine-authorizations-offer-alternative-mrna](https://www.science.org/content/article/novavax-s-long-awaited-covid-19-vaccine-authorizations-offer-alternative-mrna). Accessed July 7th.
- 462 37. Wong MCS, Wong ELY, Cheung AWL, et al. COVID-19 Vaccine Hesitancy in a City with Free
463 Choice and Sufficient Doses. *Vaccines (Basel)* **2021**; 9(11).
- 464 38. Latkin C, Dayton L, Yi G, Jaleel A, Nwosu C, Limaye R. COVID-19 vaccine delay: An
465 examination of United States residents' intention to delay vaccine uptake. *Hum Vaccin*
466 *Immunother* **2021**; 17(9): 2903-13.
- 467 39. Planès S, Villier C, Mallaret M. The nocebo effect of drugs. *Pharmacol Res Perspect* **2016**;
468 4(2): e00208.
- 469 40. Amanzio M, Mitsikostas DD, Giovannelli F, Bartoli M, Cipriani GE, Brown WA. Adverse
470 events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A
471 systematic review. *Lancet Reg Health Eur* **2022**; 12: 100253.

472

473